Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF

Markousis-Mavrogenis, G. et al. (2021) Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, (doi: 10.1093/cvr/cvab235) (PMID:34264317) (Early Online Publication)

[img] Text
246985.pdf - Accepted Version
Restricted to Repository staff only until 15 July 2022.



Aims: The exploration of novel immunomodulatory interventions to improve outcome in heart failure (HF) is hampered by the complexity/redundancies of inflammatory pathways, which remain poorly understood. We thus aimed to investigate the associations between the activation of diverse immune processes and outcomes in patients with HF. Methods and Results: We measured 355 biomarkers in 2,022 patients with worsening HF and an independent validation cohort (n = 1,691) (BIOSTAT-CHF index and validation cohorts), and classified them according to their functions into biological processes based on the Gene Ontology classification. Principal component analyses were used to extract weighted scores per process. We investigated the association of these processes with all-cause mortality at 2-year follow-up. The contribution of each biomarker to the weighted score(s) of the processes was used to identify potential therapeutic targets. Mean age was 69 (±12.0) years and 537 (27%) patients were women. We identified 64 unique overrepresented immune-related processes representing 188 of 355 biomarkers. Of these processes, 19 were associated with all-cause mortality (10 positively and 9 negatively). Increased activation of “T-cell costimulation” and “response to interferon gamma/positive regulation of interferon gamma production” showed the most consistent positive and negative associations with all-cause mortality respectively, after external validation. Within T-cell costimulation, inducible co-stimulator-ligand (ICOSLG), CD28, CD70, and tumor necrosis factor superfamily member-14 (TNFSF14) were identified as potential therapeutic targets. Conclusions: We demonstrate the divergent protective and harmful effects of different immune processes in HF and suggest novel therapeutic targets. These findings constitute a rich knowledge base for informing future studies of inflammation in HF.

Item Type:Articles
Additional Information:BIOSTAT-CHF was funded by the European Commission [FP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29]. The study was in part supported by a grant from the European Research Council (ERC CoG 818715,SECRETE-HF, to R.A.d.B.).
Status:Early Online Publication
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Markousis-Mavrogenis, G., Tromp, J., Ouwerkerk, W., Fereirra, J. P., Anker, S.D., Cleland, J.G., Dickstein, K., Filippatos, G., Lang, C.C., Metra, M., Samani, N.J., de Boer, R.A., van Veldhuisen, D. J., Voors, A. A., and van der Meer, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Cardiovascular Research
Publisher:Oxford University Press
ISSN (Online):1755-3245
Published Online:15 July 2021
Copyright Holders:Copyright © 2021 The Authors
First Published:First published in Cardiovascular Research 2021
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record